Spanish start up to develop therapeutic HPV vaccine


A Madrid – About 70% of all women will become infected with papilloma viruses (HPV) at least once in their lifetime. Now, the Spanish vaccine specialist Chimera Pharma SL (Madrid) has signed an exclusive licensing and cooperation agreement with the German Cancer Research Centre (DKFZ) in Heidelberg. Under the agreement, the two partners will develop, a therapeutic vaccine against cervical cancer to prevent women who are already infected with HPV from developing cancer, and to eradicate existing cancer prestages. Chimera has got exclusive world-wide rights to commercialise thevaccine.

Huge market promise

The market for a vaccine that kills the cancer-causing virus subtypes seems to be extremely promising. Sanofi-Pasteur MSD, which licensed IP from Chimera’s German cooperation partners under Prof. Harald zur Hausen and Dr. Angel Cid-Arregui, has made EUR1.3bn revenues with the prophylactic HPV vaccine Gardasil® since its market launch in June 2006.
Together with our Spanish partners, we will develop a protein vaccine against HPV16 and HPV18, which are linked to cervical cancer,” Cid-Arregui told EuroBiotechNews. The vaccine will be based on fusion proteins of three HPV envelope protein domains with the HBSAg envelope protein of the Hepatitis-B virus, which forms empty immunogenic virus envelopes. In addition to this, the virus shells can transport further proteins that stimulate the immune system.
“Similar to our patented (US-PTO 7,201,908) vaccine candidate, we have demonstrated the preclinical efficacy of our new compound,” says Cid-Arregui. The young Spanish company – part of Madrid-based Grupo Bionostra – is currently beginning toxicological studies, and is planning to establish GMP production by February, and to file an application for clinical development by summer 2009. Like many biotech companies that develop compounds to Phase 2 for outlicensing to big pharma, Chimera currently does not have the resources for full clinical development. Thus, at the moment outlicencing to a big pharma company seems the most probable exit



Madrid – Nowhere in the world, is the concentration of GM-sceptics higher than it is in Europe, but their reign is not supreme. On the south-western tip of the continent, Spain stands out for its “science-based agricultural...



Seville – Genetrix S.L. and the Botín Foundation will channel a 6m over the next three years into the new company Axontherapix SL. The public-private partnership will seek to develop an effective therapy for Parkinson’s Disease....



Pamplona – With a record-setting Biospain this year, the Spanish biotech industry has underpinned its role as a premier player in the sector in southern Europe. More than 1,400 business representatives flocked to Pamplona, where...



Bilbao – Spanish Progenika Biopharma S.A has gained the green light for sale of its LPLchip in Europe. The DNA chip, which has achieved the CE mark, detects approximately 120 mutations in the lipoprotein lipase (LPL) gene and...



Madrid – Responding to the current debate surrounding the reactome array investigation, Manuel Ferrer from the Institute of Catalysis and Petrochemistry in Madrid told EuroBiotechNews his team would “clarify all the scientific...



Madrid – When Chinese Premier Wen Jiabao met his Spanish colleague Jose Luis Rodriguez Zapatero on August 31st, he talked about the Mediterranean country’s role as an important economic partner for China, and said cooperation...



Madrid/Braunschweig - Spanish and German scientists who last year reported a groundbreaking technology that is able to identify the whole set of biochemical reactions in bacteria or cells, together with the enzymes involved, have...



Barcelona – While the cash-strapped Spanish government is being stripped of its AAA grade investment rating, one of the giants of the country’s life science industry is on a spending spree. Grifols, a producer of plasma protein...



Barcelona/Nantes – Biomarker-specialist TcLand Expression in Nantes has found an ally in the Vall d’Hebron University Hospital Research Institute (HVIR) in Barcelona. The French company and the Spanish clinic will work together...

Displaying results 21 to 30 out of 181

< Previous 21-30 Next >

© 2007-2015 BIOCOM


LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Product of the week



All Events


Frankfurt am Main (DE)


Stock list

All quotes


  • MEDIGENE8.76 EUR2.10%
  • EPIGENOMICS5.31 EUR1.53%
  • MOLOGEN4.99 EUR1.42%


  • SARTORIUS160.55 EUR-5.36%
  • WILEX4.05 EUR-3.57%


  • 4SC4.66 EUR258.5%
  • SYNGENTA421.00 CHF28.8%
  • BASILEA134.80 CHF18.0%


  • CYTOS0.62 CHF-39.2%
  • MEDIGENE8.76 EUR-28.0%
  • CO.DON2.85 EUR-17.4%


  • WILEX4.05 EUR406.3%
  • 4SC4.66 EUR323.6%
  • FORMYCON27.20 EUR294.2%


  • MOLOGEN4.99 EUR-54.0%
  • BIOFRONTERA2.30 EUR-24.6%
  • THERAMETRICS0.07 CHF-22.2%

No liability assumed, Date: 27.05.2015

Current issue

All issues